Oxofluoxymesterone
Oxofluoxymesterone (developmental code name U-6596), or ketofluoxymesterone, is an androgen and anabolic steroid (AAS) which was never marketed. It was assessed in the treatment of breast cancer in women in the 1970s and showed effectiveness similar to that of other AAS. The drug is the 11-dehydrogenated analogue and a metabolite of fluoxymesterone.
Clinical data | |
---|---|
Other names | U-6596; Ketofluoxymesterone; 11-Oxofluoxymesterone; 11-Ketofluoxymesterone; 9α-Fluoro-11-oxo-17α-methyltestosterone; 9α-Fluoro-17α-methylandrost-4-en-17β-ol-3,11-dione |
Routes of administration | By mouth |
Drug class | Androgen; Anabolic steroid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H27FO3 |
Molar mass | 334.431 g·mol−1 |
3D model (JSmol) | |
| |
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.